Q-omics provides the consensus-scored MIR1913 profile across patient tissues and cancer cell-line models. MIR1913 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR1913 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, MIR1913 RNA expression shows 6,041 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LUAD, and LSCC as cancer lineages where MIR1913 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1913 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1913 survival associations across molecular data types. MIR1913 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1913 RNA expression–survival associations across cancer types. High MIR1913 expression shows unfavorable associations in UVM, LIHC, KIRC, READ, THCA and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR1913 RNA expression.
This table summarizes MIR1913 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1913. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1913 shows higher tumor expression in LUAD, BRCA, LUSC and THCA. The LUAD box plot shows higher MIR1913 RNA expression in tumor versus normal tissue (log2 FC = +0.230, t-test p = .016).
This table shows molecular features associated with MIR1913 in patient tissues and cancer cell lines. In patient samples, MIR1913 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
